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Mapping Bromodomains in breast 
cancer and association with clinical 
outcome
Javier pérez-pena1, Raquel páez1, Cristina Nieto-Jiménez1, Verónica Corrales sánchez1, 
eva M. Galan-Moya1, Atanasio pandiella2, Balázs Győrffy3,4 & Alberto ocana1,5
A specific family of proteins that participate in epigenetic regulation is the bromodomain (BRD) family 
of proteins. In this work, we aimed to explore the expression of the BRD family at a transcriptomic 
level in breast cancer, and its association with patient survival. mRNA level data from normal breast 
and tumor tissues were extracted from public datasets. Gene set enrichment analysis (GSEA) was 
performed to identify relevant biological functions. The KM Plotter Online tool was used to evaluate 
the relationship between the presence of different genes and patient clinical outcome. mRNA level 
data from HER2+ breast cancer patients sensible and resistant to trastuzumab were also evaluated. 
The BRD family was an enriched function. In HER2 positive tumors the combined analyses of BRD2, 
BAZ1A, TRIM33 and ZMYND8 showed a detrimental relapse free survival (RFS). Similarly, the combined 
analysis of BRD2, BAZ1A, PHIP, TRIM33, KMT2A, ASH1L, PBRM1, correlated with an extremely poor 
overall survival (OS). The prognosis was confirmed using an independent dataset from TCGA. Finally, 
no relation between expression of BRD genes and response to trastuzumab was observed in the HER2 
population. Upregulation of some BRD genes is associated with detrimental outcome in HER2 positive 
tumors, regardless trastuzumab treatment.
Identification of oncogenic vulnerabilities with potential to be targeted therapeutically is a main goal in breast 
cancer1,2. Transcription factors (TFs) have been described as deregulated in cancer and linked with the oncogene-
sis of several malignancies including hematologic and solid tumors3. However, until very recently, pharmacolog-
ical inhibition of their expression was not achievable.
Epigenetic regulation can indirectly modify the expression of TFs and, therefore, affect tumor progression3. 
A specific family of proteins that participate in the epigenetic modulation of transcription is the bromodomain 
(BRD) family of proteins4. Around 61 BRD modules can be combined in at least 42 different proteins4. Through 
the recognition of acetylated lysine residues on histone tails, they play a key role in the epigenetic control of gene 
transcription recruiting relevant transcriptional proteins and also acting as scaffolds for these proteins4,5. A sub-
group that has gained attention is the BET family of proteins that compromised four members including BRD2, 
BRD3, BRD4 and BRDT (Bromodomain and Extraterminal proteins)6,7. Agents aiming to inhibit their function 
have been developed just recently, and they are currently in clinical evaluation at different stages, demonstrating 
a good toxicity profile6,8. In addition, they have shown activity in different solid tumors through the reduction of 
the expression of key TFs, including c-MYC or FOXM1, among others9–11.
Breast cancer is a heterogeneous disease, in which amplification of the tyrosine kinase receptor HER2, the 
expression of the estrogen receptor, or the lack of both molecular alterations guides their prognosis and therapeu-
tic approach2,12. The HER2 positive subgroup represents around 20% of all tumors. Although novel anti-HER2 
therapies, like the antibody pertuzumab or the antibody drug conjugate, trastuzumab-emtansine (TDM-1), have 
demonstrated to improve patient survival, most metastatic tumors are still incurable13. In a disease with multiple 
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molecular alterations like breast cancer, where combinations of agents can augment clinical efficacy, the identifi-
cation of novel vulnerabilities with potential to be exploited therapeutically is a main objective14,15.
In this work, we aimed to explore the expression of the BRD family of proteins in breast cancer and its associa-
tion with patient survival. Using transcriptomic analyses, we observed that the BRD family of proteins was highly 
expressed in this tumor type, and the expression of some of them was associated with poor progression free and 
overall survival. Indeed, the combined expression of some of BRD genes strongly predicted poor outcome. Using 
an in silico evaluation we observed that the expression of these genes did not predict response to trastuzumab in 
patients. Finally, in other tumor subtypes, some of the family members were amplified and linked with prognosis.
Results
Functional transcriptomic profile of breast tumors identify BRD family as enriched. First, 
we performed a transcriptomic analysis using several datasets (GSE21422, GSE26910, GSE3744, GSE65194, 
GSE42568) comparing normal breast with the four different breast cancer subtypes, including basal-like, lumi-
nal A and B, and HER2 enriched. GSEA identified several functions as deregulated, as shown in Fig. 1A. The 
Figure 1. (A) Gene set enrichment network designed using Cytoscape (as described in material and methods), 
comparing normal versus breast tumoral tissue (all breast cancer subtypes). GeneSets overexpressed in the tumoral 
phenotype are displayed in shades of orange-red; and those overexpressed in the normal phenotype are displayed in 
shades of blue. (B) ES Score profile and locations of “FOXM1 pathway” and “BRD proteins” members on the rank 
ordered list. Positive NES defines tumoral phenotype enrichment. (C) 3D structure of the common BRD domain 
shared by all the proteins coded by these genes, and subclassification of the BRD proteins into their families.
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“FOXM1 pathway” was the function more upregulated, but components of this family have already been studied 
in breast cancer16,17, so it was not the focus of our attention (Fig. 1A). Instead, we focused on BRD family genes, 
which were also clearly upregulated, and there are several therapeutic strategies against them in clinical devel-
opment6. The BRD family had a net enrichment score of 1.8 supporting the relevance of this family (Fig. 1B). 
Figure 1C show the classification of the eight subfamilies of BRD containing proteins with the 3D structure.
Upregulation of individual genes and outcome in breast cancer subtypes. Analyses of raw tran-
scriptomic data confirmed deregulation of most of the genes included in this family at different degree, depending 
on the breast cancer subtype (Fig. 2A).
Next, we intended to explore the role of these genes in relation to clinical outcome. For this purpose, we use 
the online tool KM Plotter, which associates gene expression level with prognosis18. Overexpression of several 
BRD genes was linked with detrimental relapse free survival (RFS) in breast tumors (Fig. 2B). This relation was 
Figure 2. (A) Bar graph showing Fold Change expression values of genes included in the BRD family, 
comparing normal tissues and each breast cancer subtype. (B,C) Bar graph representing relapse free survival 
(RFS) hazard ratio values (B), and overall survival (OS) hazard ratio values (C), for each breast cancer subtype 
based on genes included in BRD family. Data was extracted from the KM plotter online tool as described in 
material and methods.
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also observed for overall survival (OS), being the HER2+ subgroup the subtype in which more BRD genes were 
related with patient’s outcome (Fig. 2C).
Selection of genes associated with relapse free survival. We selected those upregulated genes in 
HER2+ patients associated with worse RFS. Ten upregulated genes were linked with detrimental outcome: 
BRD2 [HR = 1.86 (1.23–2.81), log rank p = 0.0027], BAZ1A [HR = 1.83 (1,23–2,72), log rank p = 0.0026], PHIP 
[HR = 1.63 (1.1–2.42), log rank p = 0.014], BRD7 [HR = 1.57 (1.02–2.41), log rank p = 0.037], SP100 [HR = 1.51 
(1.02–2.25), log rank p = 0.04], TRIM24 [HR = 1.57 (1.07–2.32), log rank p = 0.021], TRIM33 [HR = 2.02 (1.32–
3.09), log rank p = 0.00091], ZMYND8 [HR = 2.46 (1.67–3.61), log rank p = 2.1e−06], ZMYND11 [HR = 1.67 
(1.13–2.45), log rank p = 0.0089] and PBRM1 [HR = 1.6 (1.01–2.55), log rank p = 0.043] (Fig. 2B). Of note, the 
combined analysis of BRD2, BAZ1A, TRIM33, and ZMYND8, the genes more associated with poor outcome, 
showed a detrimental RFS that was higher than each gene analyzed individually [HR = 2.85 (1.77–4.6), log rank 
p = 7.1e−06] (Fig. 3A,B).
A multivariate analysis of this signature with variables like MKI67, ESR1 and ERB2 did not show any associa-
tion with RFS except for ESR (p = 0.0199) (Supplementary Table 2A).
A seven genes signature strongly predicted detrimental overall survival. Next, we selected 
those upregulated BRD genes in HER2+ patients related with worse OS. Eight genes met both criteria: BRD2 
[HR = 2.79 (1.46–5.33), log rank p = 0.0012], BAZ1A [HR = 3.58 (1.87–6.82), log rank p = 3.7e−05], PHIP [HR = 3 
(1.17–7.71), log rank p = 0.017], TRIM33 [HR = 2.26 (1.09–4.67), log rank p = 0.024], KMT2A [HR = 3.07 (1.45–
6.5), log rank p = 0.0021], ZMYND8 [HR = 2.07 (1.08–3.97), log rank p = 0.025], ASH1L [HR = 2.82 (1.28–6.23), 
log rank p = 0.0075], and PBRM1 [HR = 3.11 (1.37–7.05), log rank p = 0.0041] (Fig. 2C and 4A). Finally, the 
combined analysis of BRD2, BAZ1A, PHIP, TRIM33, KMT2A, ASH1L, and PBRM1, the genes more associated 
with poor prognosis, showed an extremely detrimental survival [HR = 309860758.25 (0-inf), log rank p = 0.0016] 
(Fig. 4A,B). Notably, all patients with low expression of these genes were long term survivors. To confirm this 
result, we performed an independent validation using the TCGA breast cancer dataset19. Unfortunately, this data-
set contains only 157 HER2 positive breast cancer patients with OS data. As seen in Fig. 4C, the seven genes 
signature demonstrated poor outcome regardless of this limited number of patients [HR = 2.93 (1.05–8.19), log 
rank p = 0.032.]
Finally we did a multivariate analysis with this seven gene signature including those variables included in the 
datasets from kmplotter such as MKI67, ESR1 and ERBB2. As shown in Supplementary Table 2B, not association 
with outcome was found, demonstrating the independence of the signature.
Opportunities for target inhibition. Then, we searched for compounds in preclinical and clinical devel-
opment that aim to inhibit the activity of the proteins coded by this family of genes. As shown in Supplementary 
Table 1, some of them are currently in preclinical or clinical development, like BI-9564 against BRD7, and 
OTX015 targeting BRD2, among others.
Figure 3. (A) Association of BRD2, BAZ1A, TRIM33 and ZMYND8 expression with relapse free survival in 
HER2+ tumors. (B) Association of the combined analyses of the four genes with overall survival in HER2+ 
tumors. Data was obtained as described in material and methods.
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BRD genes predict outcome in other breast cancer subtypes. Some BRD family members predicted 
worse outcome in other breast cancer subtypes, although to a lesser extent. In Basal-like patients, ZMYND11 
was overexpressed and associated with worse both OS [HR = 3.77 (1.65–8.58), log rank p = 0.00069] and RFS 
[HR = 1.56 (1.15–2.12), log rank p = 0.0039] (Supplementary Fig. 1). In luminal A patients, overexpression 
of BAZ1A correlated with worse prognosis: OS [HR = 1.58 (1.09–2.29), log rank p = 0.015], RFS [HR = 1.25 
(1.05–1.48), log rank p = 0.012] (Supplementary Fig. 2); and in luminal B tumors, we identified four genes 
linked with poor prognosis, BRD2: OS [HR = 1.8 (1.21–2.67), log rank p = 0.003], RFS [HR = 1.46 (1.19–1.77), 
log rank p = 0.00018]; ATAD2: OS [HR = 2.09 (1.03–4.23), log rank p = 0.038], RFS [HR = 1.37 (0.98–1.9), log 
rank p = 0.061]; BRD7: OS [HR = 1.69 (1.09–2.63), log rank p = 0.017], RFS [HR = 1.42 (1.17–1.74), log rank 
p = 0.00051] and TRIM24: OS [HR = 1.85 (1.26–2.72), log rank p = 0.0014], RFS [HR = 1.55 (1.26–1.9), log rank 
p = 2.6e−05] (Supplementary Fig. 3). Some of these genes were amplified in breast tumors, like ZMYND11, which 
was found to be amplified in 28% of basal-like tumors (Table 1).
BRD family is not associated with resistance to trastuzumab. Finally, we explored if the relationship 
with prognosis was due to an implication of these proteins in resistance to trastuzumab therapies, or if they were 
just a molecular alteration present in HER2 breast tumors. For this purpose, we used a trastuzumab resistant cell 
line (BT-RH), generated in our laboratory as described in Material and Methods. First, we evaluated the tran-
scriptional status of BRD genes in this cell line compared to parental non-resistant BT474 cells. Figure 5A shows 
that BRD family was enriched in BT474 comparing to BT-RH cells. Indeed, individualized analysis of each gene 
also indicated that PCAF, BRWD3, ATAD2B, and SMARCA2 were more than 1.5-fold underexpressed in BT-RH.
Next, we evaluated if these results could be reproduced in patients. To do so, we used data from the Long-HER 
study contained at GSE44272, in which patients treated with trastuzumab were classified in two groups: respond-
ers and not responders20. No clear enrichment was observed in trastuzumab resistant patients (Fig. 5B). Only 
ZMYND8 was found to be overexpressed in patients with worse response to Trastuzumab. Finally, by using an 
Figure 4. (A) Association of BRD2, BAZ1A, PHIP, TRIM33, KMT2A, ASH1L and PBRM1 individually with 
overall survival in HER2+ tumors. (B) Association of the combined analyses of the seven genes with overall 
survival in HER2+ tumors. (C) Association of the combined analyses of the seven genes with overall survival in 
HER2+ tumors using data from TCGA dataset.
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integrated response database (as described in material and methods), we confirmed that the BRD family of pro-
teins was not directly related to a worse response to Trastuzumab (Table 2).
Discussion
In this article, we identify a family of proteins that can predict detrimental survival in breast cancer, particularly 
in HER2 positive tumors, regardless the treatment of choice. Some of these genes were also implicated in patients’ 
outcome in other breast cancer subtypes.
Breast cancer is a heterogeneous disease in which several molecular alterations exist, and, among them, the 
overexpression of HER2 is observed in around 20% of breast tumors13. HER2 is an oncoprotein that is necessary 
to initiate the tumor, as it is expressed in premalignant lesions, but is not sufficient to promote cancer progression 
and dissemination, as it requires the presence of other molecular alterations14 In this context, the identification of 
additional vulnerabilities beyond the mere presence of HER2 is a main objective.
Anti-HER2 strategies are given during all period of time of the disease, contributing to the improvement in 
survival of patients with advanced disease21. However, administration of other treatments, like chemotherapy or 
anti-estrogens, in estrogen receptor positive tumors (luminal B tumors), can clearly augment the efficacy of tras-
tuzumab alone13. This demonstrates, at a clinical level, that other oncogenic vulnerabilities beyond the presence 
of HER2 do exist, and the search of therapeutic strategies against them should be pursued. Examples of stud-
ies in clinical development using this approach are those that evaluate CDK4/6 inhibitors in combination with 
anti-HER2 therapies22. Of note, this potential effect does not involve resistance to the current therapy.
In our article, we describe a family of genes linked with detrimental prognosis in HER2 positive tumors, but 
not associated with response to trastuzumab, what suggests and additional vulnerability in HER2 cancers. Of 
note, we observed the upregulation of some of these genes associated with outcome in some other subtypes. Of 
note multivariate analyses including MKI67, ESR1 and ERBB2 measured by immunohistochemistry did not show 
any association with clinical outcome, except for ESR1 with RFS. This last finding suggests that hormone receptor 
positive tumors have a slightly different behavior, probably as they belong to the Luminal B subtype.
Some of them can be inhibited pharmacologically, like is the case of BRD2 or BRD7, and it is anticipated that 
specific drugs against many others will be developed in the near future. BRD2 is a key TF with a relevant role in 
cell cycle progression; indeed, complete knockout of BRD2 in mice induces lethality23. Other identified gene was 
ATAD2, which has been previously implicated in the transcription regulation of genes by the ER24,25; although no 
data exist in HER2 positive breast tumors.
In line with this, we have identified that ZMYND11 is amplified in 28% of basal-like tumors and associ-
ated with detrimental prognosis, suggesting that manipulations of this gene could be therapeutically exploited. 
However, data regarding the role of this protein in breast cancer support that low levels are associated with det-
rimental prognosis, demonstrating its different function and role depending on the tissue and tumor of origin26.
This work is the result of an extensive in silico study, but we acknowledge some limitations, as not preclinical 
work with cell lines or animal models has been performed. In addition no confirmation using immunohisto-
chemistry has been done. Then, further assessment of the effect on the inhibition of each of the genes identified 
is required for future studies.
Gene BRD2 BAZ1A PHIP TRIM33 ZMYND8 PBRM1 ZMYND11 ATAD2 BRD7 TRIM24
Breast Cancer 
(METABRIC, 
2051 samples)
No classification
Amplification 0.98 1.41 1.07 0.73 4.29 0.1 4.05 24.23 1.12 2.15
Mutation — — — — — 1.66 — — — —
Deep Deletion 0.05 0.54 0.05 — — 0.15 0.39 — 0.1 —
Multiples alterations — — — — — — — — — —
Breast 
Invasive 
Carcinoma 
(TCGA, Cell 
2015) (818 
samples)
Her2—positive 
breast tumors 
(120 samples)
Amplification 0.83 2.5 — — 4.17 — 2.5 26.67 — —
Mutation — 1.67 0.83 0.83 0.83 2.5 — 0.83 0.83 1.67
Deep Deletion — — — — — 0.83 0.83 — 0.83 0.83
Multiples alterations — — — — — — — — — —
Invasive ductal 
cancer (Luminal 
A) (201 samples)
Amplification 1 1.99 0.5 — 3.98 0.5 0.5 11.44 1 —
Mutation — — — 0.5 1 0.5 0.5 1 0.5 1
Deep Deletion — — 0.5 — — 0.5 — — — —
Multiples alterations — — — — — — — — — —
Invasive ductal 
cancer (PAM50 
Luminal B) (122 
samples)
Amplification — 5.74 0.82 0.82 5.74 — — 28.69 0.82 0.82
Mutation 0.82 2.46 0.82 0.82 — 0.82 — 1.64 0.82 0.82
Deep Deletion — — — — — 0.82 — — 0.82 —
Multiples alterations — — — — — — — 1.64 — —
Invasive ductal 
cancer (PAM50 
Basal—like) (107 
samples)
Amplification 4.67 2.8 — 0.93 5.61 — 28.04 38.32 — 4.67
Mutation 0.93 2.8 0.93 — — 0.93 — 0.93 — 0.93
Deep Deletion — — — 0.93 — — — — 2.8 0.93
Multiples alterations — — — — — — — — — —
Table 1. Percentage of clinical cases with molecular alterations described in the genes associated with clinical 
outcome classified by breast cancer subtypes. Data was obtained as described in material and methods.
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In conclusion, here we have mapped the expression of the BRD family of proteins in breast cancer, particularly 
in HER2 positive tumors, and showed their association with outcome. The data presented here opens the oppor-
tunity for further studies exploring the functional effect of the inhibition of these genes on oncogenic properties 
in different breast cancer subtypes.
Methods
Whole genome transcription profiling and Gene-set enrichment analyses. mRNA data from nor-
mal breast and tumor tissue (basal-like, Luminal A, Luminal B and HER2+) were extracted from public datasets 
(GEO DataSet accession numbers: GSE21422, GSE26910, GSE3744, GSE65194 and GSE42568). Affymetrix CEL 
files were downloaded and analyzed with the Affymetrix Expression Console. We further performed gene set 
Figure 5. (A) Enrichment Score (ES) comparing BT474 and BT-RH cell lines (upper panel). Bar graph showing 
Fold Change expression values of genes included in the BRD family, comparing BT474 and BT-RH (lower 
panel). (B) ES Score comparing long trastuzumab responder patients and non-responders patients (upper 
panel). Bar graph showing Fold Change expression values of genes included in the BRD family, comparing long 
trastuzumab responder patients and non-responders patients (lower panel).
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enrichment analysis (GSEA) to identify transcription related functions that varied between normal and tumor tis-
sues. 58 Gene sets were collected from the Molecular Signatures Database (MSigDB) (http://www.broadinstitute.
org/gsea/msigdb/), including 53 from Gene Ontology (GO) biological process and one constructed by ourselves 
with BRD family proteins; data were analyzed by GSEA with parameter set to 1.000 gene-set permutations. This 
analysis yields an enrichment score. When this score is positive (e.g. the gene set is overrepresented by top ranked 
genes) the gene set is considered upregulated. Contrary, the gene set is considered downregulated when the score 
is negative. The network of gene sets interactions was constructed by using Cytoscape software (version 3.4.0). 
Affymetrix CHP files were analyzed with Affymetrix Transcriptome Analysis Console 3. Only genes with maxi-
mum 0.05 p-value differential expression between control and tumor were selected.
outcome analyses. The KM Plotter Online Tool (http://www.kmplot.com)18 was used to evaluate the rela-
tionship between the presence of different genes and patient clinical outcomes in different breast cancer subtypes. 
This publicly available database allowed us to investigate overall survival (OS) and relapse-free survival (RFS) in 
basal-like, luminal A, luminal B, HER2+ and triple negative breast cancers. Breast cancer subtypes were defined 
depending of their expression of ESR1 and HER2. Thus, Basal-like were defined as ESR1−/HER2−; Luminal A as 
ESR1+/HER2−/MKI67 low; Luminal B as ESR1+/HER2−/MKI67 high or ESR1+/HER2+; HER2+ as ESR1−/
HER2+; and Triple negative as ER−/PR−/HER2−. The best performing threshold between low and high expres-
sion was used as a cutoff.
TCGA dataset19 were used to confirm of RFS and OS of the identified signatures.
Transcriptomic profiling of trastuzumab resistant cell lines and patients. An in vitro cellular 
model of trastuzumab resistance was generated from BT474 cells, grown in Dulbecco´s modified Eagle medium 
(DMEM) containing antibiotics and 10% FBS. To obtain such model, BT474 cells, were plated at low density and 
grown in the presence of 50 nM trastuzumab for 6 months. Trastuzumab-resistant cells were pooled, generating 
a cell population that was named BT-RH (for “Resistant to Herceptin™”) cells. Total RNA was extracted and 
purified using the RNeasy Mini Kit (Qiagen). Biotinylated complementary RNA was then synthesized (Enzo Life 
Sciences) and hybridized to HG-U133 plus 2.0 GeneChip oligonucleotide arrays (Affymetrix), according to the 
manufacturer’s instructions. Quantitation of fluorescence intensities of probesets was done using the GenArray 
Scanner (Hewlett Packard). This process was repeated three independent times. For the microarray data analysis, 
Affymetrix CEL files generated in each different experiment were imported into the Expression Console software 
and normalized using the RMA algorithm.
mRNA data from HER2+ breast cancer tissues from patients sensible and resistant to treatment with 
Trastuzumab were extracted from a public dataset (GEO DataSet accession numbers: GSE44272). Affymetrix 
CEL files were downloaded and analyzed with Affymetrix Expression Console. Affymetrix CHP files from both 
cell lines and patients tissues were analyzed with Affymetrix Transcriptome Analysis Console 4. Only genes with 
maximum 0.05 p-value differential expression between control and tumor were selected.
Prediction of Trastuzumab response analyses. We used a database of transcriptomic datasets with 
available response and treatment data used to evaluate the relationship between the expression of those genes 
of interest and patients response to different treatments, including Trastuzumab. A Pubmed search using the 
keywords “breast cancer”, “survival”, “treatment”, and “response”, lead us to the identification of 2,108 breast 
cancer samples who received chemotherapy treatment and for whom the gene expression was measured using 
Affymetrix HGU133A and HGU133A plus 2.0 microarrays. We used those in which trastuzumab was included 
in the treatment.
Gene 
symbol Gene Name
Mann-Whitney 
test p-value
Fold 
Change AUC P-value
Family II
BRD2 Bromodomain containing 2 0.063 0.9 0.579 0.031
BAZ1A Bromodomain adjacent to zinc finger domain protein 1A 0.072 0.94 0.577 0.035
Family III PHIP Pleckstrin homology domain interacting protein 0.18 0.88 0.557 0.092
Family IV BRD7 Bromodomain containing 7 0.11 0.86 0.568 0.054
Family V
SP100 SP100 nuclear antigen 0.16 0.83 0.56 0.078
TRIM24 Tripartite motif containing 24 0.32 0.9 0.542 0.16
TRIM33 Tripartite motif containing 33 0.87 1 0.508 0.44
FamilyVI KMT2A Lysine (K)-specific methyltransferase 2A; uncharacterized LOC101929115 0.023 1 0.597 9.90E-03
Family VII
ZMYND8 Zinc finger, MYND-type containing 8 0.38 1.1 0.537 0.19
ZMYND11 Zinc finger, MYND-type containing 11 0.02 0.85 0.599 9.30E-03
Family VIII
ASH1L Ash1 (absent, small, or homeotic)-like (Drosophila) 0.25 0.9 0.562 0.12
PBRM1 Polybromo 1 0.14 1.2 0.579 0.068
Table 2. Predictive response to Trastuzumab treatment values of genes both overexpressed and related to worse 
outcome in HER2+ patients obtained as described in material and methods.
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statistical analyses. Kaplan-Meier plots were drawn to visualize the survival differences. Cox proportional 
hazards regression was computed to explore the association between gene expression and outcomes. Multiple 
genes were combined into a signature by using their mean expression. Statistical significance was defined as 
p < 0.05. In Gene Set Enrichment Analysis (GSEA), FDR < 0.25 was considered a statistically significant differ-
ence. Multivariate analysis was performed including MKKI67, ESR1 and ERBB2 using the dataset from kmplotter 
and measured by immunohistochemistry staining.
Data Availability
The datasets analyzed during the current study are available in GSE21422 (https://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE21422), GSE26910 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE26910), 
GSE3744 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE3744), GSE65194 (https://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE65194), GSE42568 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?ac-
c=GSE42568), and GSE44272 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE44272) repositories.
The normalization of the CEL files of these 5 studies resulted in our breast cancer functional transcriptome 
profile generated during the current study.
Microarray data from BT474 and BTRH are now available through the GEO repository database in GSE119397.
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